To obtain a clear-eyed view of the current state of partnering between biopharma companies and the VA, In Vivo spoke with John Bardi, vice-president of government affairs for Otsuka America Pharmaceutical Inc. Otsuka, a key player in the CNS therapeutic space, is interested in the potential of tie-ups between its research operations and the VA’s ORD division. In doing so, the company emphasizes the importance of addressing two logistical factors close to the heart of every innovative drug developer: quality and speed.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?